A real-world study of 1,898 adults with asthma found that dupilumab and tezepelumab produced nearly identical exacerbation rates (22% each) after matching. Dupilumab users had slightly higher corticosteroid use and more adverse events, while both groups showed reduced eosinophil levels. Using data from 69 U.S. health care organizations between 2015 and 2023, researchers concluded that both biologics achieved comparable asthma control. According to lead author Adeel Nasrullah, MD of BronxCare Health System, the findings support tailoring treatment based on patient comorbidities, side effect profiles, and access rather than differences in efficacy.